people experience TBI globally1
of TBIs are of mild severity2
people experience TBI globally1
of TBIs are of mild severity2
The NanoDx™ System offers an objective alternative for assessing patients suspected of mild or moderate TBI at the point of care—quickly and cost-effectively*. Using our patented nano biosensor technology, the NanoDx™ Tbit™ test delivers accurate measurement of three biomarkers indicative of brain injury.
Glial Fibrillary Acidic Protein (GFAP)
GFAP acts like a clear reliable “red flag” that quickly reveals structural brain damage.
S100 Calcium-Binding Protein B (S100B)
Elevated or increasing S100B levels after initial trauma could signal secondary injury (e.g., ischemia, cerebral edema) before it becomes clinically apparent through imaging or neurological assessment.
Ubiquitin C-terminal Hydrolase-L1 (UCH-L1)
UCH-L1 can be viewed as the brain’s “distress signal” when brain cells become injured or damaged.
Definitive assessment helps avoid misdiagnosed patients.
Accelerate clinical decisions with lab-accurate tests in 2 minutes.
In a pre-clinical feasibility study (n=100) test demonstrated 100% sensitivity and 0 false negatives.
Delivers lab-accurate results with just a fingerstick of blood.